NASDAQ:RPRX - Royalty Pharma Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $51.88
  • Forecasted Upside: 15.53 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$44.90
▼ -1.73 (-3.71%)
1 month | 3 months | 12 months
Get New Royalty Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RPRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RPRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$51.88
▲ +15.53% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Royalty Pharma in the last 3 months. The average price target is $51.88, with a high forecast of $56.00 and a low forecast of $47.00. The average price target represents a 15.53% upside from the last price of $44.90.

Hold

The current consensus among 9 contributing investment analysts is to hold stock in Royalty Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/16/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/15/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/14/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/13/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2020UBS GroupUpgradeNeutral ➝ Buy$52.00 ➝ $51.00Low
i
7/14/2020Evercore ISIInitiated CoverageHoldHigh
i
7/13/2020Bank of AmericaInitiated CoverageBuy$55.00High
i
7/13/2020CitigroupInitiated CoverageNeutral$50.00High
i
7/13/2020Morgan StanleyInitiated CoverageEqual Weight$51.00High
i
7/13/2020SunTrust BanksInitiated CoverageBuy$56.00High
i
7/13/2020UBS GroupInitiated CoverageNeutral$52.00High
i
7/13/2020JPMorgan Chase & Co.Initiated CoverageNeutral$50.00High
i
7/13/2020CowenInitiated CoverageOutperform$55.00High
i
7/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$47.00High
i
(Data available from 6/14/2016 forward)
Royalty Pharma logo
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and 5 development-stage product candidates in various therapeutic areas, such as rare disease, oncology, neurology, infectious disease, cardiology, and diabetes. The company has royalties on various product, such as Cystic fibrosis franchise, including Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio; HIV franchise comprising Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza, and Biktarvy; Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas, and Nesina; Tysabri, Imbruvica, Xtandi, Promacta, Farxiga/Onglyza, Prevymis, Emgality, Crysvita, Erleada, IDHIFA, Trodelvy, Nurtec ODT, Tazverik, and Evrysdi; and other products, such as Bosulif, Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy, and Soliqua, as well as Tecfidera, Letairis, Lyrica, Remicade, Humira, Prezista, Rotateq, and Thalomid. Royalty Pharma plc was founded in 1996 and is based in New York, New York.
Read More

Today's Range

Now: $44.90
$44.46
$46.53

50 Day Range

MA: $42.36
$39.85
$46.63

52 Week Range

Now: $44.90
$34.80
$56.50

Volume

2,336,400 shs

Average Volume

2,582,072 shs

Market Capitalization

$27.26 billion

P/E Ratio

28.06

Dividend Yield

1.51%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Royalty Pharma?

The following sell-side analysts have issued stock ratings on Royalty Pharma in the last twelve months: Bank of America Co., Citigroup Inc., Cowen Inc, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, SunTrust Banks, Inc., The Goldman Sachs Group, Inc., UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for RPRX.

What is the current price target for Royalty Pharma?

8 Wall Street analysts have set twelve-month price targets for Royalty Pharma in the last year. Their average twelve-month price target is $51.88, suggesting a possible upside of 15.5%. SunTrust Banks, Inc. has the highest price target set, predicting RPRX will reach $56.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $47.00 for Royalty Pharma in the next year.
View the latest price targets for RPRX.

What is the current consensus analyst rating for Royalty Pharma?

Royalty Pharma currently has 5 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RPRX, but not buy more shares or sell existing shares.
View the latest ratings for RPRX.

What other companies compete with Royalty Pharma?

How do I contact Royalty Pharma's investor relations team?

Royalty Pharma's physical mailing address is 110 E 59th Street, New York NY, 10022. The biopharmaceutical company's listed phone number is 212-883-0200 and its investor relations email address is [email protected] The official website for Royalty Pharma is www.royaltypharma.com.